ABMC Adds Three International Distributors; New Partners Add Sales Breadth in Europe, Middle East.Business Editors KINDERHOOK, N.Y.--(BUSINESS WIRE)--June 11, 2002 American Bio Medica medica (māˑ·dē·k Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ABMC ABMC American Battle Monuments Commission ABMC Alexian Brothers Medical Center (Illinois) ABMC Aviation Battle Management Concept ABMC Arrowbear Music Camp (California) ) today announced that it has signed agreements with three major international distributors of drug testing products. B. M. Browne (UK) Ltd., PharmaSwiss, and DIMED FZCO FZCO Free Zone Company have been granted exclusive distribution rights in specified markets for ABMC's proprietary drug testing products in the United Kingdom; the former Yugoslav republics of Croatia, Slovenia, and Serbia; and the Persian Gulf Persian Gulf, arm of the Arabian Sea, 90,000 sq mi (233,100 sq km), between the Arabian peninsula and Iran, extending c.600 mi (970 km) from the Shatt al Arab delta to the Strait of Hormuz, which links it with the Gulf of Oman. region, respectively. B.M Browne is a leading distributor of medical and safety products to clinical and workplace clients. It has been awarded exclusive rights to solicit orders for ABMC's Rapid Drug Screen(R) products in the clinical and workplace markets within the United Kingdom, including Scotland and Wales Wales, Welsh Cymru, western peninsula and political division (principality) of Great Britain (1991 pop. 2,798,200), 8,016 sq mi (20,761 sq km), west of England; politically united with England since 1536. The capital is Cardiff. . Based in Zug, Switzerland, PharmaSwiss is a pharmaceutical distributor employing over 70 people, including 38 salespeople, and offices in Slovenia, Croatia, and Serbia. PharmaSwiss will sell Rapid Drug Screen in these markets, primarily to the clinical laboratory market. DIMED FZCO is based in Dubai, United Arab Emirates United Arab Emirates, federation of sheikhdoms (2005 est. pop. 2,563,000), c.30,000 sq mi (77,700 sq km), SE Arabia, on the Persian Gulf and the Gulf of Oman. , and provides drug screening products for the workplace market, specifically companies involved in oil drilling and export operations. DIMED will distribute Rapid Drug Screen to clients in the United Arab Emirates, Kuwait, Qatar, Oman, and Bahrain. "These agreements are important achievements for ABMC, because they will have an immediate impact on the expansion of our sales base for Rapid Drug Screen into international clinical and workplace markets," said ABMC chairman and chief executive officer Gerald Moore
About American Bio Medica Corporation American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate, onsite drugs-of-abuse diagnostic kits and support services support services Psychology Non-health care-related ancillary services–eg, transportation, financial aid, support groups, homemaker services, respite services, and other services worldwide. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One(TM) and Rapid Tec(TM) test for the presence or absence of drugs of abuse in urine, while its OralStat6(TM) tests for the presence or absence of drugs of abuse in saliva. ABMC was recently listed among the top ten biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. on the Deloitte & Touche 2001 Technology Fast 500, a ranking of the fastest growing companies in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the transition period ended December 31, 2001, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares. --30--bw/ny* csm
CONTACT: American Bio Medica Corporation, Kinderhook
Gerald A. Moore, 800/227-1243, Fax: 518/758-8171
gerald@americanbiomedica.com
Web: www.americanbiomedica.com
KEYWORD: NEW YORK
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL
MANAGEMENT CHANGES
SOURCE: American Bio Medica Corporation
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion